154 related articles for article (PubMed ID: 15479488)
1. Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer.
Price N
Clin Prostate Cancer; 2004 Sep; 3(2):77-9. PubMed ID: 15479488
[No Abstract] [Full Text] [Related]
2. Annual zoledronic acid: is less more?
Higano CS
J Clin Oncol; 2007 Mar; 25(9):1026. PubMed ID: 17369565
[No Abstract] [Full Text] [Related]
3. Activity of epothilone B analogues ixabepilone and patupilone in hormone-refractory prostate cancer.
Lee D
Clin Prostate Cancer; 2004 Sep; 3(2):80-2. PubMed ID: 15479489
[No Abstract] [Full Text] [Related]
4. Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.
Cameron D
Breast; 2003 Aug; 12 Suppl 2():S22-9. PubMed ID: 14659140
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates in prostate cancer: where are we and where should we go?
Saad F
J Natl Cancer Inst; 2003 Sep; 95(17):1262-3. PubMed ID: 12953073
[No Abstract] [Full Text] [Related]
6. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
Bankhead C
J Natl Cancer Inst; 2003 Sep; 95(17):1273-4. PubMed ID: 12953081
[No Abstract] [Full Text] [Related]
7. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
8. Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
Joensuu TK
Urol Int; 2008; 80(4):448-50. PubMed ID: 18587260
[TBL] [Abstract][Full Text] [Related]
9. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
10. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.
Body JJ
Breast; 2003 Aug; 12 Suppl 2():S37-44. PubMed ID: 14659142
[TBL] [Abstract][Full Text] [Related]
11. [Systemic treatment of metastatic prostate cancer].
Wörmann B; Wolff JM
Urologe A; 2010 Feb; 49(2):221-7. PubMed ID: 20180063
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
Dearnaley DP; Sydes MR; Mason MD; Stott M; Powell CS; Robinson AC; Thompson PM; Moffat LE; Naylor SL; Parmar MK;
J Natl Cancer Inst; 2003 Sep; 95(17):1300-11. PubMed ID: 12953084
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer: targeted therapy for prostate cancer metastases to bone.
Coleman R
Nat Rev Urol; 2011 May; 8(6):296-8. PubMed ID: 21587226
[No Abstract] [Full Text] [Related]
14. Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
Cai T; Bartoletti R
J Clin Oncol; 2007 Aug; 25(22):3385; author reply 3385-6. PubMed ID: 17664492
[No Abstract] [Full Text] [Related]
15. [Treatment of prostate cancer].
Romics I
Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
[No Abstract] [Full Text] [Related]
16. Choice of first-line treatment for metastatic prostate cancer.
Prescrire Int; 2013 Feb; 22(135):51. PubMed ID: 23444511
[No Abstract] [Full Text] [Related]
17. Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis.
Nozawa M; Inagaki T; Nagao K; Nishioka T; Komura T; Esa A; Kitagawa M; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uejima S; Matsuyama H; Hara I; Uemura H
Int J Clin Oncol; 2014 Aug; 19(4):693-701. PubMed ID: 23912936
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid is effective in the treatment of prostate cancer patients with bone metastases.
Maung K
Clin Prostate Cancer; 2002 Jun; 1(1):12-3. PubMed ID: 15046707
[No Abstract] [Full Text] [Related]
[Next] [New Search]